Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Bausch + Lomb Corporation is a global eye health company focused on developing, manufacturing, and commercializing products that protect, enhance, and restore vision. The company operates within the ophthalmic and vision care industries, serving both consumer and professional markets. Its core activities span contact lenses, eye care products, ophthalmic pharmaceuticals, and surgical devices, making it one of the most diversified pure-play eye health companies globally.
The company’s primary revenue drivers include contact lenses, lens care solutions, ophthalmic pharmaceuticals, and vision and surgical products used by eye care professionals. Bausch + Lomb serves optometrists, ophthalmologists, optical retailers, hospitals, and consumers. Its strategic positioning is built on a vertically integrated model, a broad and trusted brand portfolio, and a long operating history dating back to 1853. Originally founded as an optical goods retailer, the company evolved into a global eye health platform through decades of product innovation and acquisitions. In 2022, Bausch + Lomb Corporation became an independent public company following its separation from Bausch Health Companies.
Business Operations
Bausch + Lomb operates through three primary business segments: Vision Care, Opharmaceuticals, and Surgical. The Vision Care segment includes contact lenses, lens care products, and eye vitamins, representing a significant portion of company revenue. The Opharmaceuticals segment develops and markets prescription and over-the-counter eye medications addressing conditions such as glaucoma, infection, inflammation, and dry eye. The Surgical segment provides devices and consumables used in cataract and vitreoretinal procedures.
Operations are supported by a global manufacturing and distribution network, with facilities across North America, Europe, Asia-Pacific, and Latin America. The company controls proprietary lens technologies, drug formulations, and surgical platforms. Bausch + Lomb maintains commercial relationships with eye care professionals worldwide and operates through wholly owned subsidiaries rather than material joint ventures. No material dependence on a single customer or distributor has been disclosed in public filings.
Strategic Position & Investments
The company’s strategy emphasizes organic growth through innovation in contact lenses, minimally invasive surgical tools, and differentiated ophthalmic drugs. Growth initiatives focus on expanding daily disposable lens offerings, advancing preservative-free pharmaceutical formulations, and increasing penetration in emerging markets. Bausch + Lomb continues to invest in research and development to support new product pipelines across all segments.
Since becoming an independent public company, Bausch + Lomb has pursued targeted acquisitions and internal investments aligned with eye health specialization. Notable investments have included expanded manufacturing capacity and incremental product portfolio additions rather than transformative acquisitions. The company positions itself as a focused eye health leader, distinct from diversified pharmaceutical peers. Where disclosures on emerging technologies or future pipeline assets lack sufficient public detail, data is inconclusive based on available public sources.
Geographic Footprint
Bausch + Lomb is headquartered in Canada, with operational headquarters and significant management presence in the United States. The company maintains a substantial market presence across North America, Europe, Asia-Pacific, Latin America, and parts of the Middle East and Africa. Its products are sold in more than 100 countries through direct sales forces and distribution partners.
International markets represent a meaningful share of total revenue, with particularly strong positions in Europe and Asia-Pacific for vision care products. Manufacturing and R&D facilities are geographically diversified to support regional demand, regulatory compliance, and supply chain resilience. The company’s global footprint supports both developed and emerging market growth strategies.
Leadership & Governance
Bausch + Lomb is led by an executive team with deep experience in eye health, medical devices, and pharmaceuticals. The leadership philosophy emphasizes long-term value creation through scientific innovation, operational discipline, and a singular focus on vision care following the company’s separation from Bausch Health.
Key executives include:
- Brent L. Saunders – Chairman and Chief Executive Officer
- Fred Hassan – Vice Chairman
- Sam Eldessouky – Chief Financial Officer
- Yehia Hashad – Chief Research & Development Officer
- Michelle Tan – Chief Legal Officer and Corporate Secretary
- Joe Gordon – President, Vision Care
The board of directors oversees governance with an emphasis on independence, regulatory compliance, and strategic oversight consistent with publicly traded healthcare companies.